Literature DB >> 23959793

Screening, prevention, and ambitious management of diabetic macular edema in patients with type 1 diabetes.

Ryan M Tarantola, Raj K Maturi, Shalesh Kushal, Sunil Gupta.   

Abstract

Diabetic macular edema results from progressive retinopathy related to chronic hyperglycemic and inflammatory vascular damage. Loss of vision secondary to diabetic macular edema is the most common cause of vision loss in patients with diabetes. Blood glucose control remains the main means of preventing progression of retinopathy and macular edema. Recent advancements allowing more efficient mechanisms for screening patients and emerging treatments for macular edema have led to improved visual outcomes in this group of patients.

Entities:  

Mesh：

Year:  2013        PMID： 23959793     DOI： 10.1007/s11892-013-0410-z

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  41 in total

1.  Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid.

Authors:  S D Pendergast; T S Hassan; G A Williams; M S Cox; R R Margherio; P J Ferrone; B R Garretson; M T Trese
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

2.  Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study.

Authors:  J B Jonas; I Akkoyun; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

3.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

4.  Use of Joslin Vision Network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program.

Authors:  Anthony A Cavallerano; Jerry D Cavallerano; Paula Katalinic; Ann Marie Tolson; Lloyd Paul Aiello; Lloyd M Aiello
Journal:  Retina       Date:  2003-04       Impact factor: 4.256

5.  Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

Authors:  Peter A Campochiaro; David M Brown; Andrew Pearson; Thomas Ciulla; David Boyer; Frank G Holz; Michael Tolentino; Amod Gupta; Lilianne Duarte; Steven Madreperla; John Gonder; Barry Kapik; Kathleen Billman; Frances E Kane
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

6.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

7.  VEGF induces hyperpermeability by a direct action on endothelial cells.

Authors:  S Hippenstiel; M Krüll; A Ikemann; W Risau; M Clauss; N Suttorp
Journal:  Am J Physiol       Date:  1998-05

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane.

Authors:  J W Harbour; W E Smiddy; H W Flynn; P E Rubsamen
Journal:  Am J Ophthalmol       Date:  1996-04       Impact factor: 5.258

10.  Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy.

Authors:  E Stefansson; M B Landers; M L Wolbarsht
Journal:  Trans Am Ophthalmol Soc       Date:  1981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.